Abstract RCS-4 [(4-methoxyphenyl)-1-yl-(1-pentyl-1H-indol-3-yl)methanone] represents the first of several Nalkyl-3-(methoxybenzoyl)indoles identified by forensic scientists as synthetic cannabinoid (SC) designer drugs. Despite the detection of RCS-4 and several analogues (RCS-2, RCS-3, RCS-2-C4, RCS-3-C4, and RCS-4-C4) in products intended for human consumption, relatively little is known about this class of cannabinoids. The synthesis of all regioisomers of RCS-4 and their C4 homologues is described. This study also systematically explored the structure-activity relationships of this class of SCs at human CB 1 and CB 2 receptors using an in vitro fluorometric imaging plate reader membrane potential assay. All compounds demonstrated agonist activity at CB 1 (EC 50 = 54-574 nM) and CB 2 (EC 50 = 4.5-46 nM) receptors, with the C4 homologues showing a preference for CB 2 receptors over CB 1 receptors (31-42 times). Since most of the analogues (RCS-2, RCS-3, RCS-2-C4, RCS-3-C4 and RCS-4-C4) are not subject to regulation in much of the world, despite their activities towards CB 1 and CB 2 receptors, there is a possibility that these analogues will emerge on the black market.
Introduction
Herbal smoking mixtures adulterated with synthetic cannabinoids (SCs) have been available internationally as unregulated ''legal'' cannabis alternatives since approximately 2004 [1] . The earliest such product, ''Spice'', was disingenuously marketed as incense and labeled ''not for human consumption'', but was later found to contain psychoactive SCs JWH-018 (1, Fig. 1 ) and CP 47,497 (2) [2] . Like the principal bioactive component of cannabis, D 9 -tetrahydrocannabinol (D 9 -THC, 3), many SCs exert agonist activities at both cannabinoid receptor subtypes (CB 1 and CB 2 receptors), with psychoactivity attributed to CB 1 activation [3] . Unlike D 9 -THC, SC intoxication is associated with severe acute toxicity, including myocardial infarction and seizure [4] [5] [6] [7] [8] [9] [10] [11] .
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reports that 74 new SCs have been identified in marketed products since 2008, with 29 novel SCs formally notified in 2013 alone, making SCs the most rapidly expanding class of ''designer drugs'' [12] . Although early SCs had been reported by academia or the pharmaceutical industry, many recent examples are unknown in the scientific literature and appear to be the products of clandestine rational design [13] , such as N-alkylated 3-(methoxybenzoyl)indoles (4) (5) (6) (7) (8) (9) . The first reported member of this class, RCS-4 (9, also sold online as OBT-199, SR-19, BTM-4, and Eric-4) was identified by Nakajima and colleagues [14] of the Tokyo Metropolitan Institute of Public Health in January 2011, followed by the 2-methoxy regioisomer (RCS-2, 7) by the same group later that year [15] .
RCS-4 has been identified in commercial products seized in the USA [16] , Belgium [17] , South Korea [18] , and New Zealand [19] , suggesting widespread use internationally. In 2011, RCS-4 was the third most common substance identified in ''herbal highs'' products obtained in Poland [20] . A survey of SC products in Germany in 2011 found RCS-4 in a herbal blend at a concentration of 157 mg/g, one of the highest SC contents of all samples tested in that study [21] . However, various products from Japan contained RCS-4 at concentrations of 18 and 1.7 mg/g herbal matter, suggesting limited knowledge about the potency of this compound by manufacturers [14] . The N-butyl homologue of RCS-4, RCS-4-C4 (6), was found in products purchased in New Zealand in July 2011 [19] , and the regioisomeric RCS-2-C4 (4) was identified in seized products by researchers at the National Forensic Service in South Korea in October 2012 [22] . The same group also found RCS-2 (7) and RCS-3 (8) in their seizure materials until June 2013 [23] . The structures of the homologues of RCS-4, together with JWH-018, CP 47,497, and D 9 -THC are shown in Fig. 1 . Despite the global availability and popularity of N-alkyl-3-(methoxybenzoyl)indole SCs, very little is known of their pharmacology. RCS-4 is the most widely studied member of this class of SCs, and extensive metabolic profiling of RCS-4 has been reported [24] [25] [26] [27] . Forensic chemists have also focused on the development of analytical methods for detection and quantification of RCS-4 and its metabolites in human hair [28] , urine [29] [30] [31] , serum [32] , and oral fluid [33, 34] , with less attention given to RCS-2, and a complete dearth of information regarding the other RCS analogues. Indeed, a method for the detection and quantification of RCS-2, RCS-3, RCS-4, and RCS-4-C4 in human whole blood represents the only report of RCS-3 in the scientific literature [35] .
The aim of the present work was to prepare and structurally characterize compounds 4-9, and to determine and compare the functional activity of these novel SCs at cannabinoid receptors in vitro. All compounds were screened against CB 1 and CB 2 receptors in a fluorometric imaging plate reader (FLIPR) membrane potential assay to suggest structure-activity relationships for this class of SCs.
Materials and methods

General chemical synthesis details
The synthesis of 4-9 is shown in Fig. 2 . All reactions were performed under an atmosphere of nitrogen or argon unless otherwise specified. Toluene was dried over sodium wire and distilled from sodium benzophenone ketyl. Dichloromethane and methanol were distilled from calcium hydride. Anhydrous N,N-dimethylformamide (DMF) (SigmaAldrich, St. Louis, MO, USA) was used as purchased. Commercially available chemicals (Sigma-Aldrich) were used as purchased. Analytical thin-layer chromatography was performed using Merck aluminum-backed silica gel 60 F254 (0.2 mm) plates (Merck, Darmstadt, Germany), which were visualized using shortwave (254 nm) ultraviolet fluorescence. Flash chromatography was performed using Merck Kieselgel 60 (230-400 mesh) silica gel. Melting points were measured in open capillaries using a Stuart SMP10 melting point apparatus (Bibby Scientific, Staffordshire, UK) and are uncorrected. Nuclear magnetic resonance spectra were recorded at 300 K using either a Bruker AVANCE DRX400 (400.1 MHz) or AVANCE III 500 Ascend (500.1 MHz) spectrometer (Bruker, Bremen, Germany) . The data are reported as chemical shift (d ppm) relative to the residual protonated solvent resonance, relative integral, multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, sep = septet, m = multiplet), coupling constants (J Hz) and assignment. Assignment of signals was assisted by correlation spectroscopy (COSY), distortionless enhancement by polarization transfer (DEPT), heteronuclear single quantum cohenerence (HSQC), and heteronuclear multiple-bond correlation (HMBC) experiments where necessary. Low resolution mass spectra (LRMS) was recorded using electrospray ionization (ESI) recorded on a Finnigan LCQ ion trap mass spectrometer (ThermoFisher Scientific, Waltham, MA, USA). Elemental analysis was obtained from the Chemical Analysis Facility in the Department of Chemistry and Biomolecular Sciences, Macquarie University, Australia.
General procedure for 1-alkylation of indole
A cooled (0°C) suspension of sodium hydride (60 % dispersion in mineral oil, 1.20 g, 30 mmol, 1.5 equiv.) in DMF (35 ml) was treated slowly with a solution of indole (2.34 g, 20.0 mmol) in DMF (5 ml), warmed to ambient temperature and stirred for 10 min. The mixture was cooled to 0°C, treated portionwise with the appropriate 1-bromoalkane (21.0 mmol, 1.05 equiv.), warmed to ambient temperature and stirred for 1 h. The reaction was poured portionwise onto ice water (400 ml) and extracted with ethyl acetate (4 9 50 ml). The combined organic extracts were washed with H 2 O (2 9 200 ml), brine (200 ml), dried (MgSO 4 ), and the solvent evaporated under reduced pressure. The crude products were purified using flash chromatography.
1-Butylindole (10)
Indole was treated with 1-bromobutane (2.26 ml) according to the general procedure, and the crude material was purified by flash chromatography, eluting with hexane (R f 0.26) to give 10 as a colorless oil (2.90 g, 84 %).
was purified by flash chromatography, eluting with hexane (R f 0.32), to give 11 as a pale yellow oil (3.75 g, 80 %). 1 [37] .
General procedure for 3-acylation of 1-alkylindoles A solution of the appropriate carboxylic acid (1.2 mmol, 1.2 equiv.) in dichloromethane (4 ml) was treated with (COCl) 2 (205 ll, 2.4 mmol, 2.4 equiv.) followed by DMF (1 drop). After stirring for 1 h, the solution was evaporated in vacuo, and the crude acid chloride was used immediately in the following step.
A cooled (0°C) solution of appropriate 1-alkylindole (1.0 mmol, 1.0 equiv.) in dichloromethane (3 ml) was treated dropwise with a solution of 1 M Me 2 AlCl in hexane (1.5 ml, 1.5 mmol, 1.5 equiv.) and stirred for 30 min. To this solution was added dropwise a solution of the freshly prepared acid chloride in dichloromethane (3 ml), and the reaction was stirred for 4 h. The reaction was quenched by dropwise addition to a solution of 1 M aq. HCl (6 ml), the layers were separated, and the aqueous phase was extracted with dichloromethane (2 9 10 ml). The combined organic layers were washed with sat. aq. NaHCO 3 (2 9 10 ml), brine (10 ml), dried (MgSO 4 ), and the solvent evaporated under reduced pressure. The crude products were purified by flash chromatography. (1-Pentyl-1H-indol-3-yl)(2-methoxyphenyl)methanone (7)
Treating 11 (187 mg, 1.0 mmol) with 2-methoxybenzoic acid (183 mg, 1.2 mmol) according to the general procedure gave, following purification by flash chromatography (1-Pentyl-1H-indol-3-yl)(4-methoxyphenyl)methanone (9) 
Ultraviolet absorption spectroscopy
Ultraviolet (UV) absorption spectroscopy was performed using a Cary 60 UV-Vis Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). UV absorbances of solutions of 4-9 in methanol (0.001 % w/v) in quartz cuvettes were recorded over 200-400 nm.
Gas chromatography-mass spectrometry
All SCs were analyzed by gas chromatography-mass spectrometry (GC-MS) using a ThermoQuest Trace gas chromatograph with Finnigan Polaris Q ion trap mass spectrometer (ThermoQuest, Madison, CT, USA) in positive ion electron ionization (EI) mode and Phenomenex ZB Wax column (30 m 9 0.25 mm internal diameter, 0.25 lm film thickness; Phenomenex, Torrance, CA, USA) with helium gas as carrier at 1.3 ml/min. The conditions were: electron energy, 70 eV; injector temperature, 250°C; injection, split mode (10:1); injection volume, 1 ll; oven temperature program, 40°C (2 minhold) and increase at a rate of 20°C/min to 270°C (20 min-hold for 4 and 7, 40 min hold for 5, 6, 8, and 9); transfer line temperature, 250°C; scan range, m/z 46-650 (5 min solvent delay).
X-ray data collection
Solid 9 was recrystallized from isopropanol-H 2 O to give colorless needle crystals by slow evaporation at ambient temperature. The single-crystal X-ray diffraction experiments were carried out at the Faculty of Pharmacy, University of Sydney using a Bruker APEX-II CCD-based diffractometer with an X-ray wavelength of 0.71073 Å (Mo Ka) and at an experimental temperature of 150 K. The single crystal of 9 was mounted on the tip of a thin glass fiber with a minimum amount of Paratone N oil, which acted as both an adhesive and a cryoprotectant, and inserted in the cold N 2 stream of an Oxford Cryosystem COBRA cooler (Oxford Cryosystems, Oxford, UK). X-ray diffraction data were collected using 0.3°Dx-scans, maintaining the crystal-to-detector distance at 6.0 cm. A total of 1664 frames were collected. The diffraction data were integrated using SAINT? [38] , which included corrections for Lorentz, polarization and absorption effects. Unit cell parameters for 9 at 150 K were refined from 999 reflections. The structure was solved using Direct Methods (SHELX-S) [39] , and refined using full-matrix leastsquares (SHELXL) [39] . All non-hydrogen atoms were treated as anisotropic, while hydrogen atoms were placed in idealized positions, with U eq set at 1.5 times that of the parent atom. 
In vitro pharmacological assessment of 4-9
Mouse AtT-20 neuroblastoma cells stably transfected with human CB 1 or human CB 2 have been previously described [40, 41] and were cultured in Dulbecco's modified Eagle's medium containing 10 % fetal bovine serum (FBS), 100 U penicillin/streptomycin, and 300 lg/ml G418. Cells were passaged at 80 % confluency as required. Cells for assays were grown in 75 cm 2 flasks and used at 90 % confluence. The day before, the assay cells were detached from the flask with trypsin/EDTA (Sigma-Aldrich) and resuspended in 10 ml of Leibovitz's L-15 media supplemented with 1 % FBS, 100 U penicillin/streptomycin and 15 mM glucose (membrane potential assay and Ca5 calcium assay). The cells were plated in volume of 90 ll in black-walled, clear-bottomed, 96-well microplates (Corning, Oneonta, NY, USA) that had been precoated with poly-L-lysine (Sigma-Aldrich). Cells were incubated overnight at 37°C in ambient CO 2 .
Membrane potential was measured using a FLIPR membrane potential assay kit (blue) from Molecular Devices (Sunnyvale, CA, USA), as described previously [42] . The dye was reconstituted with assay buffer of composition (mM): NaCl 145, HEPES 22, Na 2 HPO 4 0.338, NaHCO 3 4.17, KH 2 PO 4 0.441, MgSO 4 0.407, MgCl 2 0.493, CaCl 2 1.26, glucose 5.56 (pH 7.4, osmolarity 315 ± 5). Prior to the assay, cells were loaded with 90 ll/well of the dye solution without removal of the L-15, giving an initial assay volume of 180 ll/well. Plates were then incubated at 37°C at ambient CO 2 for 45 min. Fluorescence was measured using a FlexStation 3 (Molecular Devices) microplate reader with cells excited at a wavelength of 530 nm and emission measured at 565 nm. Baseline readings were taken every 2 s for at least 2 min, at which time either drug or vehicle was added in a volume of 20 ll. The background fluorescence of cells without dye or dye without cells was negligible. Changes in fluorescence were expressed as a percentage of baseline fluorescence after subtraction of the changes produced by vehicle addition, which was \ 2 % for drugs dissolved in assay buffer or dimethyl sulfoxide (DMSO). The final concentration of DMSO was not more than 0.1 %.
Data were analyzed with PRISM (GraphPad Software Inc., San Diego, CA, USA), using four-parameter nonlinear regression to fit concentration-response curves. In all plates, a maximally effective concentration of WIN 55,212-2 (Cayman Chemical, Ann Arbor, MI, USA) was added to allow for normalization between assays.
Results and discussion
The synthesis of 4-9 is shown in Fig. 2 . Indole was alkylated with either 1-bromobutane or 1-bromopentane to quantitatively afford the desired N-alkylindoles 10 and 11, respectively. Subjecting N-alkylindoles 10 and 11 to acylation under Okauchi conditions [43] with freshly prepared 2-methoxybenzoyl chloride, 3-methoxybenzoyl chloride, or 4-methoxybenzoyl chloride gave the desired products in excellent yields after chromatographic purification.
RCS-2-C4, RCS-4-C4, RCS-2 and RCS-4 could be recrystallized from isopropanol/water to afford highly crystalline material, whereas RCS-3-C4 and RCS-3 were obtained as oils. Attempts to crystallize RCS-3-C4 and RCS-3 using various high vacuum and low temperature techniques were unsuccessful. A highly prismatic single crystal of RCS-4 was selected from the bulk mixture, allowing the generation of the first X-ray crystal structure for this class of SCs. An Oak Ridge Thermal-Ellipsoid Plot Program representation of RCS-4 is shown in Fig. 3 . All bond lengths and angles were as expected (full details of X-ray data collection and tables of bond lengths and angles available in the Supplementary Material), with the pentyl chain in a fully extended conformation and the methoxybenzene group out-of-plane with the indole ring.
All SCs were analyzed using GC-MS, and total ion current chromatograms (TICs) and EI mass spectra for Nbutyl-3-(methoxybenzoyl)indoles (4) (5) (6) and N-pentyl analogues (7-9) are shown in Fig. 4 . All N-butyl-3-(methoxybenzoyl)indoles demonstrated molecular ion peaks at m/z 307, while their N-pentyl analogues showed molecular ion peaks at m/z 321. The major fragmentation ions for 4-6 were m/z 264 and m/z 200. The former arises from cleavage of the butyl chain between the two carbon atoms most proximal to the indole nitrogen (C1-C2), while the latter can be attributed to loss of the methoxyphenyl ring. Other fragmentation ions observed were m/z 172 and 135, each representing the fragments remaining after cleavage of the methoxybenzoyl unit. For 4, the ion at m/z 144 was prominent, and represents a protonated species featuring loss of the methoxyphenyl ring and pentyl chain. The peak at m/z 290 likely results from the loss of a hydroxyl group, although the mechanism is unclear.
The fragmentation patterns for 7-9 were analogous, with fragmentation ion at m/z 264 appearing due to corresponding fragmentation of the pentyl chain C1-C2 bond, and the ion at m/z 214 consistent with loss of the methoxyphenyl ring. Similarly, cleavage of the whole methoxybenzoyl group of 7-9 gave m/z 186 and m/z 135. As for 4, the ion at m/z 144 was observed for 7, as well as a peak at m/z 290, corresponding to the loss of 17 mass units.
The ultraviolet absorption spectra of 4-9 are shown in Fig. 5 , and peak absorbances are similar for each corresponding N-butyl and N-pentyl regioisomer, as expected.
The cannabinoid activities of RCS analogues 4-9 at CB 1 and CB 2 receptors, together with that of the phytocannabinoid D 9 -THC, a partial agonist at CB 1 and CB 2 , are shown in Table 1 . Murine AtT-20 neuroblastoma cells were stably transfected with human CB 1 or CB 2 receptors, and activities of D 9 -THC and 4-9 were evaluated using a FLIPR membrane potential assay whereby endogenously expressed G protein-gated inwardly rectifying K ? channels (GIRKs) are activated by agonists at the coexpressed CB 1 or CB 2 receptors [42, 44] . The maximum effects of 4-9 were compared to the high efficacy CB 1 /CB 2 receptor full agonist WIN 55,212-2, which produced a maximal decrease in fluorescence, corresponding to cellular hyperpolarization, of 29 ± 2 % in AtT-20-CB 1 cells and 31 ± 3 % in AtT-20-CB 2 cells. None of the compounds produced a significant change in the membrane potential of wild type AtT-20 cells, which did not express CB 1 or CB 2 receptors.
All RCS analogues activated CB 1 and CB 2 receptors. RCS-2 (54 nM) had about fivefold greater potency than D 9 -THC (250 nM) for CB 1 receptor-mediated activation of GIRK; the other compounds had a similar potency to D 9 -THC (Table 1) . D 9 -THC is a low efficacy CB 2 agonist, and in the assay of GIRK activation in AtT20-CB 2 , its effects at 10 lM were only 13 % of that of WIN 55,212-2.
WIN 55,212-2 was more potent at stimulating a cellular hyperpolarization in AtT-20-CB 2 cells than AtT-20-CB 1 cells, displaying about fivefold CB 2 preference. The Npentyl indoles RCS-2, RCS-3, and RCS-4 had a similar maximal effect to WIN 55,212-2 at both CB 1 and CB 2 receptors, and also showed a similar CB 2 preference (Table 1 ; Fig. 6 ). This indicates that these drugs are also high efficacy agonists. The N-butyl indoles RCS-2-C4, RCS-3-C4, and RCS-4-C4 had generally similar efficacies to WIN 55,212-2 at CB 2 receptors, but were significantly more potent than WIN 55,212-2; and their CB 2 selectivity was [ 30-fold (Table 1) . Interestingly, their CB 1 efficacy fell between that of WIN 55,212-2 and D 9 -THC, indicating a relatively moderate CB 1 efficacy (Fig. 6) .
The 2-methoxy-substituted indoles (RCS-2, RCS-2-C4) were both relatively more potent than the corresponding 3-methoxy regioisomers, while the 4-methoxy compounds were the least potent at both CB 1 and CB 2 receptors (Table 1) . It should be noted that while the potency of any drug effect depends on the number of receptors expressed in the system under study, and we did not directly measure the number of receptors in our AtT-20-CB 1 and -CB 2 cells at the time of these assays; WIN 55,212-2 is recognized as having a higher affinity for CB 2 receptors than CB 1 receptors in binding assays [45, 46] , so it is likely that the CB 2 preference of the RCS analogues is genuine, and not an artifact of our expression systems.
Conclusions
This study represents the first pharmacological characterization of the designer drug RCS-4, as well as several of its regioisomers and N-butyl analogues of forensic interest. A general synthetic route to RCS-4 and its analogues was demonstrated, and this may prove useful to forensic toxicologists and cannabinoid researchers for the preparation of other N-alkyl-3-acylindoles of relevance. RCS-4 and its analogues were tested as agonists of CB 1 and CB 2 receptors in a FLIPR membrane potential assay. Preliminary structure-activity relationships suggest that an N-butyl substituent on the indole ring primarily confers functional selectivity for CB 2 receptors, while an N-pentyl group at the same position increases potency at CB 1 receptors, leading to a net reduction in CB 2 selectivity. The position of the methoxy group on the benzoyl ring appeared to have little effect on activity, but it should be noted that the 2-position conferred the greatest potency at CB 1 and CB 2 in both the N-butyl and N-pentyl series. This study demonstrates that RCS-4, as well as its regioisomers and their C4 homologues, are all actively cannabimimetic in vitro. Since several RCS-4 regioisomers and their C4 homologues are not subject to regulation in much of the world, there is a possibility that these analogues will emerge on the black market.
